Ashland (ASH) Q1 2025 earnings summary

Executive summary

• Q1 FY2025 sales declined 14% year-over-year to $405 million, with adjusted EBITDA down 13% to $61 million and adjusted EPS down 38% to $0.28, reflecting portfolio optimization, lower pricing, and higher turnaround costs; net loss was $165 million due to a $183 million Avoca impairment.

• Portfolio optimization actions, including the nutraceutical divestiture and Avoca sale, are nearly complete, positioning the company for more stable, profitable growth.

• Adjusted EBITDA margin improved by 30 basis points to 15.1% despite lower volumes and pricing, supported by production recovery and cost actions.

• 3.0 million shares repurchased in the last twelve months, with $620 million remaining under the current authorization.

• Strategic priorities focus on cost savings, globalizing high-margin business lines, and innovation-driven growth.

Financial highlights

• Q1 sales were $405 million, down 14% year-over-year, mainly due to portfolio actions; adjusted EBITDA was $61 million, down 13%; adjusted EPS was $0.28, down 38%.

• Gross profit margin increased 290 basis points to 28.1% due to production recovery and portfolio actions.

• Operating loss was $179 million, mainly due to the Avoca impairment; adjusted income from continuing operations (excluding intangibles amortization) was $14 million.

• Free cash flow for Q1 was negative $26 million, reflecting seasonality and plant turnarounds; cash and equivalents at quarter-end were $219 million, with total liquidity of $815 million.

• Debt to capital ratio increased to 34% from 32% sequentially; net debt at $1.1 billion, leverage ratio approximately 2.4x.

Outlook and guidance

• Full-year FY2025 sales expected in the range of $1.90 billion to $2.05 billion; adjusted EBITDA guidance is $430 million to $470 million.

• Guidance reaffirmed despite ongoing uncertainty in China, Europe, and FX headwinds; cost savings and growth catalysts expected to support results.

• Organic volumes expected to be flat to up for the year, with sequential improvement anticipated from Q2 onward.

• FY25 outlook includes a $15 million headwind from restructuring and lost gross profit due to portfolio actions.

• Management expects 200–250 basis points improvement in adjusted EBITDA margins post-optimization.